home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  May 24, 2022
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 452 active entries

MIR Preclinical Services

800 Technology Drive
Ann Arbor 48108
United States of America, Michigan

Phone: (734) 821-1063
Fax: (734) 821-1066

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


MIR Preclinical Services (MIR) is a contract research organization (CRO) located in Ann Arbor, Michigan. MIR specializes in the preclinical assessments and evaluation of novel anti-cancer and anti-inflammatory therapeutic agents. The company's senior leadership has over 100 years of drug discovery experience utilizing xenograft, orthotopic and transgenic animal models. MIR offers additional services such as preclinical efficacy testing, non-invasive imaging, pharmacodynamics, pharmacokinetics, in vitro testing and consulting.

MIR employs a wide array of novel imaging technologies including preclinical MRI, CT (µCT), high resolution PET (µPET), bioluminescence and fluorescence imaging to measure response to therapy at anatomical, functional, and molecular levels. We can measure biological processes, such as signal transduction, angiogenesis, apoptosis (proteases), DNA damage, and other biologically relevant processes important in animal models of human disease. MIR also performs basic research to develop these technologies and actively seeks collaborations to further imaging in the field of drug discovery.

Selected Categories:
Product Company   Service Company
- Research
- Research
- Services

Last update of this entry: June 15, 2010

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2022 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.